Innoviva, Inc. INVA Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Cost Reimbursement | $2.7M— | $0-100% | $1.3M— | —— | |
| Giapreza | $73.61M+33.7% | $55.04M+33.3% | $41.29M— | —— | |
| Royalty | $236.48M-2.2% | $241.73M+1.2% | $238.85M-11.6% | $270.31M-31.0% | |
| Xacduro | $74.39M+253% | $21.07M— | —— | $0— | |
| Percentage Of Royalty Payable On Net Sales by Product | |||||
| Xerava | 2.3%0.0pp | 2.3%— | —— | —— | |
| Royalty Expense by Product | |||||
| Durlobactam | $0— | $0— | $0— | —— | |
| Giapreza | $4.5M+32.4% | $3.4M+36.0% | $2.5M— | —— | |
| Research And Development Expense by Product | |||||
| External Services | $15.71M+112% | $7.41M-63.1% | $20.05M-18.7% | $24.67M— | |
| Internal Expenses | $5.53M-11.5% | $6.25M-55.0% | $13.87M-17.3% | $16.77M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Innoviva, Inc. break its business down?
- Innoviva, Inc. (INVA) reports revenue by product across 4 parts — Cost Reimbursement, Giapreza, Royalty and Xacduro. Each is extracted from the segment footnotes and tracked over time.
- Where does Innoviva, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Innoviva, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
